Modelling the economic impact of recombinant activated Factor VII and activated prothrombin-complex concentrate in the treatment of a mild to moderate bleed in adults with inhibitors to clotting Factors VIII and IX at a comprehensive care centre in the UK

References

• Colvin BT, Hay CRM, Hill FGH et al. The incidence of Factor VIII inhibitors in the UK, 1990-93. British Journal of Haematology 1995; 89: 908–910.
   PubMed Web of Science ®Google Scholar
• Lusher JM. Early treatment with recombinant Factor VIIa results in greater efficacy with less product. European Journal of Haematology 1998; 61 (Suppl. 63): 7–10.
   Web of Science ®Google Scholar
• Lusher JM. Recombinant activated Factor VII for treatment of intramuscular haemorrhages: a comparison of early versus late treatment. Blood Coagulation and Fibrinolysis 1998; 9 (Suppl. 1): S111–S114.
   Web of Science ®Google Scholar
• Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated Factor VII in patients with Factor VIII inhibitors: the advantages of early intervention. British Journal of Haematology 1999; 104: 22–26.
   Google Scholar
• Key NS, on behalf of the US rFVIIa Home Therapy Study Group. Efficacy of recombinant activated Factor VII when administered in the home to control joint, muscle, and mucocutaneous bleeds in haemophilia patients with inhibitors. Blood Coagulation and Fibrinolysis 1998; 9 (Suppl. 1): S153.
   Google Scholar
• English PJ, Sheppard EM, Wensley RT. Factor VIII inhibitor bypassing activity. Lancet 1976; 2: 207.
   PubMed Web of Science ®Google Scholar
• Kurczynski EM, Penner JA. Activated prothrombin concentrate for patients with Factor VIII inhibitors. New England Journal of Medicine 1974; 291: 164.
   PubMed Web of Science ®Google Scholar
• Pollock A, Lewis, MJ. Factor VIII inhibitor bypassing activity. Lancet 1976; 2: 43.
   PubMed Web of Science ®Google Scholar
• Stenbjerg S, Jørgensen J. Activated F IX concentrate (aPCC) used in the treatment of haemophilic patients with antibody to F VIII. Acta Medica Scandinavica 1978; 203: 471–476
   PubMedGoogle Scholar
• Sjamsoedin LJM, Heijnen L, Mauser- Bunschoten EP et al. The effect of activated prothrombin-complex concentrate (aPCC) on joint and muscle bleeding in patients with haemophilia A and antibodies to Factor VIII. New England Journal of Medicine 1981; 305: 717–721.
   PubMed Web of Science ®Google Scholar
• Hilgartner MW, Knatterud GL and the aPCC Study Group. The use of Factor eight inhibitor by-passing activity (aPCC Immuno) product for treatment of bleeding episodes in haemophiliacs with inhibitors. Blood 1983; 61: 36–40.
   PubMed Web of Science ®Google Scholar
• Hilgartner M, Aledort L, Andes A, Gill J, and the members of the aPCC Study Group. Efficacy and safety of vapor- heated anti-inhibitor coagulant complex in haemophilia patients. Transfusion 1990; 30: 626–630.
   Google Scholar
• Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P and the members of the French aPCC study group. Multicenter retrospective study on the utilisation of aPCC in France in patients with Factor VIII and Factor IX inhibitors. Thrombosis and Haemostasis 1997; 77: 1113–1119.
   PubMed Web of Science ®Google Scholar
• Negrier C, Lee M et al. The aPCC-VH survey: Initial findings from a world-wide surveillance study. Haemophilia 2000; 6 (Suppl. 1): 279–314.
   Google Scholar
• Hay CRM, Lozier JN et al. Safety profile of porcine factor VIII and its use as hospital and home therapy for patients with haemophilia A and inhibitors. The results of an international survey. Thrombosis and Haemostasis 1996; 75: 25–29.
   PubMed Web of Science ®Google Scholar
• Stewart AJ, Hanley JP, Ludlam CA. Safety, efficacy and cost-effectiveness of home therapy with recombinant activated Factor VII in a patient with severe haemophilia A and an anti-Factor VIII inhibitor. Blood Coagulation and Fibrinolysis 1998; 9 (Suppl. 1): S93–S95.
   PubMed Web of Science ®Google Scholar
• Guest JF, Odeyemi IAO. Economic impact of recombinant activated Factor VII compared to activated prothrombin- complex concentrate in the home treatment of a minor bleed in haemophilia patients with high titre high responding inhibitors to coagulation Factors VIII and IX. Presented at the American Society for Hematology Annual Meeting, 2000 (Abstract No. 1883).
   Google Scholar
• Fink A, Kosecoff J et al. Consensus methods: Characteristics and guidelines for use. American Journal of Public Health 1984; 74: 979–983.
   PubMed Web of Science ®Google Scholar
• Netten A, Dennett J, Knight J. Unit costs of health and social care 1999. University of Kent, Canterbury. Personnel Social Services Research Unit, 1999.
   Google Scholar
• Monthly Index of Medical Specialities 2000 editions. London: Haymarket Publications Ltd.
   Google Scholar
• Department of Health. Drug Tariff May 2000 edition. London: The Stationery Office.
   Google Scholar
• Lipton RA. The economics of Factor VIII inhibitor treatment. Seminars in Haematology 1994; 31 (Suppl. 4): 37–38.
   PubMed Web of Science ®Google Scholar
• Goudemand J. Pharmaco-economic aspects of inhibitor treatment. European Journal of Haematology 1998; 61 (Suppl. 63): 24–27.
   Google Scholar
• Aledort LM. Economic aspects of haemophilia care. Haemophilia 1999; 5: 216–219.
   PubMed Web of Science ®Google Scholar
• Ludlam C. Funding arrangements within the UK. Haemophilia 1998; 2 (Suppl. 1): 13–14.
   Google Scholar